{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:50:45Z","timestamp":1787964645939,"version":"build-2784847793"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Formycon AG"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s12325-025-03138-2","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T02:00:34Z","timestamp":1741226434000},"page":"2135-2149","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A Randomised, Double-Blind Trial to Compare the Efficacy, Safety, and Immunogenicity of the Biosimilar Ustekinumab FYB202 with Reference Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis"],"prefix":"10.1007","volume":"42","clinical-trial-number":[{"clinical-trial-number":"nct04595409","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Kim","family":"Papp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9548-1550","authenticated-orcid":false,"given":"Sigrid","family":"Balser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Nopora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Rewerski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Freudensprung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Trieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"issue":"10","key":"3138_CR1","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1007\/s13555-023-01014-x","volume":"13","author":"G Girolomoni","year":"2023","unstructured":"Girolomoni G, Savage L, Gisondi P, et al. Increasing access to effective systemic treatments in patients with moderate-to-severe psoriasis: narrative review. Dermatol Ther (Heidelb). 2023;13(10):2171\u201385. https:\/\/doi.org\/10.1007\/s13555-023-01014-x.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"3138_CR2","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2024.2350440","author":"R V\u00e1zquez-S\u00e1nchez","year":"2024","unstructured":"V\u00e1zquez-S\u00e1nchez R, Navarro-D\u00e1vila M, Herr\u00e1iz ER, et al. Biosimilars and access to biologic therapy in immune-mediated diseases. Expert Opin Biol Ther. 2024. https:\/\/doi.org\/10.1080\/14712598.2024.2350440.","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"3138_CR3","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1001\/jamadermatol.2021.0221","volume":"157","author":"N Loft","year":"2021","unstructured":"Loft N, Egeberg A, Rasmussen MK, et al. Outcomes following a mandatory nonmedical switch from adalimumab originator to adalimumab biosimilars in patients with psoriasis. JAMA Dermatol. 2021;157(6):676\u201383. https:\/\/doi.org\/10.1001\/jamadermatol.2021.0221.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"3138_CR4","doi-asserted-by":"publisher","first-page":"318","DOI":"10.23736\/S2784-8671.22.07224-3","volume":"157","author":"D Giordano","year":"2022","unstructured":"Giordano D, Capalbo A, Gagliostro N, et al. Biosimilar versus originator etanercept: a real-life clinical study. Ital J Dermatol Venerol. 2022;157(4):318\u201324. https:\/\/doi.org\/10.23736\/S2784-8671.22.07224-3.","journal-title":"Ital J Dermatol Venerol"},{"issue":"6","key":"3138_CR5","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s13555-022-00732-y","volume":"12","author":"F Bellinato","year":"2022","unstructured":"Bellinato F, Gisondi P, Mason E, Ricci P, Maurelli M, Girolomoni G. Real-life effectiveness of adalimumab biosimilars in patients with chronic plaque psoriasis. Dermatol Ther (Heidelb). 2022;12(6):1303\u201311. https:\/\/doi.org\/10.1007\/s13555-022-00732-y.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"4","key":"3138_CR6","doi-asserted-by":"publisher","first-page":"723","DOI":"10.5114\/ada.2021.108442","volume":"39","author":"W Owczarek","year":"2022","unstructured":"Owczarek W, Walecka I, Nowakowska A, et al. Effectiveness of infliximab biosimilars in the treatment of moderate to severe chronic plaque psoriasis: experience of real-world data from the register of the program \u201cTreatment of moderate and severe forms of plaque psoriasis (B.47)\u201d of the National Health Fund in Poland. Postepy Dermatol Alergol. 2022;39(4):723\u20138. https:\/\/doi.org\/10.5114\/ada.2021.108442.","journal-title":"Postepy Dermatol Alergol"},{"issue":"7","key":"3138_CR7","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1001\/jamadermatol.2023.1338","volume":"159","author":"DB Phan","year":"2023","unstructured":"Phan DB, Elyoussfi S, Stevenson M, Lunt M, Warren RB, Yiu ZZN. Biosimilars for the treatment of psoriasis: a systematic review of clinical trials and observational studies. JAMA Dermatol. 2023;159(7):763\u201371. https:\/\/doi.org\/10.1001\/jamadermatol.2023.1338.","journal-title":"JAMA Dermatol"},{"issue":"9625","key":"3138_CR8","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","volume":"371","author":"CL Leonardi","year":"2008","unstructured":"Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665\u201374. https:\/\/doi.org\/10.1016\/S0140-6736(08)60725-4.","journal-title":"Lancet"},{"issue":"9625","key":"3138_CR9","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","volume":"371","author":"KA Papp","year":"2008","unstructured":"Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(08)60726-6.","journal-title":"Lancet"},{"issue":"3","key":"3138_CR10","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jdermsci.2011.05.005","volume":"63","author":"TF Tsai","year":"2011","unstructured":"Tsai TF, Ho JC, Song M, et al. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase\u00a0III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci. 2011;63(3):154\u201363. https:\/\/doi.org\/10.1016\/j.jdermsci.2011.05.005.","journal-title":"J Dermatol Sci"},{"issue":"3","key":"3138_CR11","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/j.1346-8138.2011.01347.x","volume":"39","author":"A Igarashi","year":"2012","unstructured":"Igarashi A, Kato T, Kato M, Song M, Nakagawa H, Japanese Ustekinumab Study Group. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase\u00a02\/3 clinical trial. J Dermatol. 2012;39(3):242\u201352. https:\/\/doi.org\/10.1111\/j.1346-8138.2011.01347.x.","journal-title":"J Dermatol"},{"issue":"9894","key":"3138_CR12","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","volume":"382","author":"IB McInnes","year":"2013","unstructured":"McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1\u00a0year results of the phase\u00a03, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382(9894):780\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(13)60594-2.","journal-title":"Lancet"},{"issue":"6","key":"3138_CR13","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"C Ritchlin","year":"2014","unstructured":"Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase\u00a03, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014;73(6):990\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204655.","journal-title":"Ann Rheum Dis"},{"issue":"16","key":"3138_CR14","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","volume":"367","author":"WJ Sandborn","year":"2012","unstructured":"Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn\u2019s disease. N Engl J Med. 2012;367(16):1519\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1203572.","journal-title":"N Engl J Med"},{"issue":"20","key":"3138_CR15","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","volume":"375","author":"BG Feagan","year":"2016","unstructured":"Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2016;375(20):1946\u201360. https:\/\/doi.org\/10.1056\/NEJMoa1602773.","journal-title":"N Engl J Med"},{"issue":"13","key":"3138_CR16","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381(13):1201\u201314. https:\/\/doi.org\/10.1056\/NEJMoa1900750.","journal-title":"N Engl J Med"},{"issue":"2","key":"3138_CR17","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1056\/NEJMoa0810652","volume":"362","author":"CE Griffiths","year":"2010","unstructured":"Griffiths CE, Strober BE, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362(2):118\u201328. https:\/\/doi.org\/10.1056\/NEJMoa0810652.","journal-title":"N Engl J Med"},{"issue":"8","key":"3138_CR18","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1080\/14712598.2023.2235263","volume":"23","author":"SR Feldman","year":"2023","unstructured":"Feldman SR, Reznichenko N, Berti F, et al. Randomized, double-blind, multicenter study to evaluate efficacy, safety, tolerability, and immunogenicity between AVT04 and the reference product ustekinumab in patients with moderate-to-severe chronic plaque psoriasis. Expert Opin Biol Ther. 2023;23(8):759\u201371. https:\/\/doi.org\/10.1080\/14712598.2023.2235263.","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"3138_CR19","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s40259-023-00630-5","volume":"38","author":"KA Papp","year":"2024","unstructured":"Papp KA, Lebwohl MG, Tha\u00e7i D, et al. Efficacy and safety of candidate biosimilar CT-P43 versus originator ustekinumab in moderate to severe plaque psoriasis: 28-week results of a randomised, active-controlled, double-blind, phase\u00a0III study. BioDrugs. 2024;38(1):121\u201331. https:\/\/doi.org\/10.1007\/s40259-023-00630-5.","journal-title":"BioDrugs"},{"key":"3138_CR20","unstructured":"European Medicines Agency. Stelara: summary of product characteristics. 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/stelara-epar-product-information_en.pdf. Accessed July 11, 2024."},{"issue":"4","key":"3138_CR21","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1111\/bjd.15152","volume":"176","author":"CEM Griffiths","year":"2017","unstructured":"Griffiths CEM, Tha\u00e7i D, Gerdes S, et al. The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. Br J Dermatol. 2017;176(4):928\u201338. https:\/\/doi.org\/10.1111\/bjd.15152.","journal-title":"Br J Dermatol"},{"issue":"3","key":"3138_CR22","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/bjd.16890","volume":"179","author":"A Blauvelt","year":"2018","unstructured":"Blauvelt A, Lacour JP, Fowler JF Jr, et al. Phase\u00a0III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. Br J Dermatol. 2018;179(3):623\u201331. https:\/\/doi.org\/10.1111\/bjd.16890.","journal-title":"Br J Dermatol"},{"issue":"2","key":"3138_CR23","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/bjd.18220","volume":"182","author":"J Hercogov\u00e1","year":"2020","unstructured":"Hercogov\u00e1 J, Papp KA, Chyrok V, Ullmann M, Vlachos P, Edwards CJ. AURIEL-PsO: a randomized, double-blind phase\u00a0III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis. Br J Dermatol. 2020;182(2):316\u201326. https:\/\/doi.org\/10.1111\/bjd.18220.","journal-title":"Br J Dermatol"},{"issue":"5","key":"3138_CR24","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s40257-022-00708-w","volume":"23","author":"A Menter","year":"2022","unstructured":"Menter A, Cohen S, Kay J, et al. Switching between adalimumab reference product and BI 695501 in patients with chronic plaque psoriasis (VOLTAIRE-X): a randomized controlled trial. Am J Clin Dermatol. 2022;23(5):719\u201328. https:\/\/doi.org\/10.1007\/s40257-022-00708-w.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"3138_CR25","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s40259-021-00502-w","volume":"35","author":"SR Feldman","year":"2021","unstructured":"Feldman SR, Reznichenko N, Pulka G, et al. Efficacy, safety and immunogenicity of AVT02 versus originator adalimumab in subjects with moderate to severe chronic plaque psoriasis: a multicentre, double-blind, randomised, parallel group, active control, phase\u00a0III study. BioDrugs. 2021;35(6):735\u201348. https:\/\/doi.org\/10.1007\/s40259-021-00502-w.","journal-title":"BioDrugs"},{"key":"3138_CR26","unstructured":"Otulfi. Summary of product characteristics. European Medicines Agency, Amsterdam, the Netherlands. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/otulfi. Accessed Jan 31, 2025."},{"key":"3138_CR27","unstructured":"OTULFI (ustekinumab-aauz). Prescribing information. Food and Drug Administration, Silver Spring, MD, USA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761379s001lbl.pdf. Accessed Jan 31, 2025."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03138-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03138-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03138-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T02:51:05Z","timestamp":1744858265000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03138-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["3138"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03138-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,6]]},"assertion":[{"value":"30 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kim Papp has received honoraria and\/or grants from AbbVie, Acelyrin, Akros, Alumis, Amgen, Arcutis, Bausch Health\/Valeant, Boehringer Ingelheim, Bristol Myers Squibb, Can-Fite Biopharma, Celltrion, Concert Pharmaceuticals, Dermavant, Dermira, DiCE Pharmaceuticals, DiCE Therapeutics, Evelo Biosciences, Forbion, Galderma, Horizon Therapeutics, Incyte, Janssen, Kymab, Kyowa Hakko Kirin, LEO, Lilly, Meiji Seika Pharma, Mitsubishi Pharma, Nimbus Therapeutics, Novartis, Pfizer, Reistone, Sanofi-Aventis\/Genzyme, Sandoz, Sun Pharma, Takeda, Tarsus Pharmaceuticals, UCB, and Zai Lab. Piotr Rewerski has received honoraria as a consultant for Eli Lilly and Bayer AG. Sigrid Balser, Katrin Nopora, Brigitte Freudensprung, and Michael Trieb are employees of Formycon AG.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study protocol was reviewed and approved by the independent ethics committee or institutional review board for each centre.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}